About this trial
The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.
Eligibility criteria
Qualifiers
At least 18 years of age
For stage 0: Individuals without overweight/obesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD)
Individuals with overweight/obesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD
Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD
Disqualifiers
Individuals with CKM syndrome stage 4 according to the AHA
History of coronary artery disease, myocardial infarction, coronary artery intervention
History of atrial fibrillation
History of stroke
Trial design
Treatments tested in this trial
- Not listed